958 related articles for article (PubMed ID: 26188967)
21. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
[TBL] [Abstract][Full Text] [Related]
22. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
23. Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.
León-González M; León-Peña AA; Vallejo-VIllalobos MF; Núñez-Cortés AK; Ruiz-Argüelles A; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):181-3. PubMed ID: 27623036
[TBL] [Abstract][Full Text] [Related]
24. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
26. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.
Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ito T; Ishii K; Nomura S
J Blood Med; 2017; 8():5-12. PubMed ID: 28182150
[TBL] [Abstract][Full Text] [Related]
28. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
29. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
Jung EH; Byun JM; Shin DY; Do YR; Jo JC; Lee SM; Yoon SS
Cancer Med; 2023 Apr; 12(8):9186-9193. PubMed ID: 36951655
[TBL] [Abstract][Full Text] [Related]
30. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
32. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present?
Korkmaz S; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):795-799. PubMed ID: 29153313
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
[TBL] [Abstract][Full Text] [Related]
36. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
Andreola G; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
38. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
39. Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.
Becker P; Schwebig A; Brauninger S; Bialleck H; Luxembourg B; Schulz M; Tsamadou C; Wiesneth M; Reinhardt P; Mytilineos J; Seidl C; Gattu S; Kaliakina N; Singh P; Schrezenmeier H; Seifried E; Bonig H
Transfusion; 2016 Dec; 56(12):3055-3064. PubMed ID: 27633122
[TBL] [Abstract][Full Text] [Related]
40. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
